Clinical Trials Logo

Hemoglobinuria, Paroxysmal clinical trials

View clinical trials related to Hemoglobinuria, Paroxysmal.

Filter by:

NCT ID: NCT03047746 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Unrelated And Partially Matched Related Donor PSCT w/ T Cell Receptor (TCR) αβ Depletion for Patients With BMF

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

This is a single arm pilot study using TCR alpha/beta+ T cell-depleted peripheral blood stem cells (PBSC) from closely matched unrelated donors or partially matched/haploidentical related donors for hematopoietic stem cell transplant (HSCT) in patients with acquired and inherited bone marrow failure (BMF) syndromes.

NCT ID: NCT03030183 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

Start date: April 17, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.

NCT ID: NCT02958462 Recruiting - Clinical trials for Hematologic Neoplasms

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Start date: January 16, 2017
Phase: N/A
Study type: Interventional

This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.

NCT ID: NCT02946463 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: December 12, 2016
Phase: Phase 3
Study type: Interventional

The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).

NCT ID: NCT02928991 Recruiting - Clinical trials for Bone Marrow Failure Syndromes

Fludarabine Based RIC for Bone Marrow Failure Syndromes

Start date: April 2015
Phase: Early Phase 1
Study type: Interventional

This is a pilot study to determine whether fludarabine-based reduced intensity conditioning (RIC) regimens facilitate successful donor engraftment of patients with acquired aplastic anemia (AA) and Inherited bone marrow failure (iBMF) syndromes undergoing Matched related donor bone marrow transplant (MRD-BMT).

NCT ID: NCT02605993 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: January 4, 2016
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.

NCT ID: NCT02598583 Completed - PNH Clinical Trials

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: November 12, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.

NCT ID: NCT02591862 Completed - Clinical trials for Paroxysmal Nocturnal Haemoglobinuria (PNH)

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Start date: February 2016
Phase: Phase 2
Study type: Interventional

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms.

NCT ID: NCT02588833 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.

PADDOCK
Start date: December 1, 2015
Phase: Phase 1
Study type: Interventional

The objectives of the study are to assess the safety, tolerability, preliminary efficacy and PK of multiple subcutaneous (SC) doses of pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who have not received treatment with eculizumab in the past. An exploratory objective of the study is to assess the pharmacodynamics (PD) of multiple SC doses of pegcetacoplan when administered to PNH patients.

NCT ID: NCT02534909 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria PNH

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: September 9, 2015
Phase: Phase 2
Study type: Interventional

To determine whether LFG316 can induce a hematological response, as measured by reduction in hemolytic activity, in patients with PNH.